Clinical Trial Update: Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor [Phase 2]

View source ↗

Summary

Phase 2 study of pazopanib monotherapy in patients with unresectable, metastatic neuroendocrine tumor has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor

Drugs mentioned

• Votrient (Pazopanib)

Snippet

Sponsor: Samsung Medical Center | Conditions: Neuroendocrine Tumor | Phase 2 | Status: COMPLETED